Effect of Prognostic Risk Classification on Temsirolimus Efficacy and Safety Outcomes in Patients with Relapsed/Refractory Mantle Cell Lymphoma

被引：0
|
作者：
Hess, Georg [1 ]
Kang, Lisa [2 ]
Moran, Padraig J. [3 ]
机构：
[1] Johannes Gutenberg Univ Mainz, Mainz, Germany
[2] Pfizer Inc, Collegeville, PA USA
[3] Pfizer Inc, Dublin, PA, Ireland
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1165 / 1165
页数：1
相关论文
共 50 条
  • [1] Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: A retrospective analysis
    Hess G.
    Coiffier B.
    Crump M.
    Gisselbrecht C.
    Offner F.
    Romaguera J.
    Kang L.
    Moran P.J.
    Experimental Hematology & Oncology, 4 (1)
  • [2] TEMSIROLIMUS IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: DOES PROGNOSTIC RISK AFFECT OUTCOMES?
    Hess, G.
    Kang, L.
    Moran, P.
    HAEMATOLOGICA, 2012, 97 : 101 - 101
  • [3] Clinical Efficacy and Management of Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Coiffier, Bertrand
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04): : 351 - 359
  • [4] Efficacy and Safety Of Temsirolimus In Patients With Relapsed Or Refractory Mantle Cell Lymphoma: Results From The Spanish Experience
    de la Fuente, Adolfo
    Gonzalez, Gloria
    Garcia-Carbonero, Iciar
    Garcia-Frade, Javier
    Munarriz, Javier
    Aguiar, David
    Cuevas, Beatriz
    Cuevas, Maria Victoria
    Aporta, Rafael
    Barez, Abelardo
    Callejas, Marta
    Murias, Adolfo
    Altes, Albert
    Salar, Antonio
    Sanchez-Gonzalez, Blanca
    Grande, Carlos
    Garcia-Marco, Jose A.
    Lopez, Angeles
    Moran, Marina
    Viqueira, Andrea
    Briones, Javier
    BLOOD, 2013, 122 (21)
  • [5] Temsirolimus In Relapsed and/or Refractory Mantle Cell Lymphoma
    Hoy, Sheridan M.
    McKeage, Kate
    DRUGS, 2010, 70 (14) : 1819 - 1829
  • [6] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL)
    Krekeler, G.
    Dreyling, M.
    Hess, G.
    Kalanovic, D.
    ONKOLOGIE, 2011, 34 : 269 - 269
  • [7] Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
    Samad, Nousheen
    Younes, Anas
    ONCOTARGETS AND THERAPY, 2010, 3 : 167 - 178
  • [8] Temsirolimus in Relapsed and/or Refractory Mantle Cell Lymphoma Profile Report
    Hoy, Sheridan M.
    McKeage, Kate
    BIODRUGS, 2011, 25 (03) : 193 - 195
  • [9] Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Fukuhara, Noriko
    Kitano, Toshiyuki
    Ishikawa, Takayuki
    Shibayama, Hirohiko
    Choi, Ilseung
    Hatake, Kiyohiko
    Uchida, Toshiki
    Nishikori, Momoko
    Kinoshita, Tomohiro
    Matsuno, Yoshihiro
    Nishikawa, Tomoaki
    Takahara, Satoko
    Tobinai, Kensei
    CANCER SCIENCE, 2016, 107 (12) : 1785 - 1790
  • [10] Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
    Kirschey, Sebastian
    Wagner, Susanne
    Hess, Georg
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
12345